I've idly been evaluating the immune deficiency AKA immunocompromised AKA immunosuppressed AKA autoimmunity leitmotif in First World "What We Know" industry propaganda since CLINICIANS diagnosed MS in me body 24 years ago--without benefit of genomic sequencing, pathological certainty, or Big Data mining correlative inferences d/b/a "biostatistics", incidentally.

Within the first 5 years of consultation with experts and armed with a rudimentary, secondary school education in biology, chemistry, and logic, I arrived at a conclusion, or plausible threshold, to my own risk management of malpractice by differential diagnoses: Apart from radical and cosmetic surgery and routine  mechanical recovery (bone-setting and "high-risk" organ replacement), moderne medical canon is a massive collection of misplaced precision populating descriptive speculations (primary research d/b/a "peer-reviewed" publications of abstruse and unreproducible experiments with eugenically mass-produced mice populations or eugenically mass-produced human stem cells) that has not advanced prescriptive (applied research) praxis in quite a number of "knowledge domains"--be that hematology, endocrinology, neurology, cardiology, neurology, pulmonology, or more exotic, discrete organizational divisions of uhhh sociology d/b/a abnormal health professions like epidemiologists, the accountants of defective electronic public health records.  

Accordingly, pharmacology dispensed to date is not well understood. Experts licensed to prescribe "therapeutic" formulae, approved for consumption by proprietors of government buildings, rarely encounter much less acknowledge the clinical consequences of their "bioethics" (duly noted by dearly departed Dr. MarketTrustee, my Robert). Much of analog isolated compounds, or mRNA classified, chemistry, is palliative and transitory in their effects d/b/a "disease modulating" chemistry AKA synthetic catalytic conversions expected to replace adverse chemical interactions and "normalized" homeostasis, which is not well understood either. IOW, complex interactions expressed by an "essentialized" schema of What we know about elements associated with regulation of "immune system" DNA organisms that metabolize RNA products.

atm, I hesitate to post an entry here describing my own experience reporting a confounding Rx reaction to combined "disease modulating" Rx1 and Rx2, because I've been advised by Drug 2 manufacturer's agent pharmacists and "nurse educators" as well my prescribing physician that no such ADR and no differential dosage "end-points"  have been published, so; more important, the  zeitgeist here seems to me not amenable to interrogation of units of measurement employed by experts to evaluate any pharmaceutical cost and benefit other than prescribed ineffectual SARS-CoV-2 retroviral agents d/b/a "vaccine hesitancy" and atavistic right-wing ideologues.

Dambha-Miller et al., "Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review," 19 May (print 4 Aug 2020)

We screened 3360 titles and included 112 studies with 21 different drug classes identified as influencing ACE2 activity. Ten studies were in humans and one hundred and two were in animal models. None examined ACE2 in human lungs.
[...]
Previous studies suggest that dysregulation of ACE2 activity in the lungs could promote early neutrophil infiltration and subsequent uncontrolled activation of the RAS.8 In mice models, acute lung injury was observed in response to SARS-CoV-1 spike protein, so it is plausible that similar responses will be observed with SARS-CoV-2.9 This is particularly problematic in organs containing high ACE2 such as the lungs as it may contribute to cytokine release syndrome (cytokine storm) and the subsequent respiratory failure that has been observed in those who have died from the disease.7 Many prescribed drugs in common use are known to mediate effects through the RAS pathway. Over 45 million of these prescriptions were issued in the UK last year alone, and of these, 15 million were for ACE inhibitors (ACE-I) and angiotensin receptor blockers (ARBs). Acting through the RAS pathway, these drugs may impact ACE2 regulation but their role in the COVID-19 pandemic is not clear. Given the number of people that are potentially on these drugs, it has caused substantial public concern and clinical uncertainty about continuation or cessation of prescribed medications during the pandemic.

Fang et al.,"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection", Lancet correspondence, 11 Mar 2020 (print 18 May 2020)

If this hypothesis were to be confirmed, it could lead to a conflict regarding treatment because ACE2 reduces inflammation and has been suggested as a potential new therapy for inflammatory lung diseases, cancer, diabetes, and hypertension
[...]
We suggest that patients with cardiac diseases, hypertension, or diabetes, who are treated with ACE2-increasing drugs, are at higher risk for severe COVID-19 infection and, therefore, should be monitored for ACE2-modulating medications, such as ACE inhibitors or ARBs

adalimumab indications
B cells and B lymphocyte (TNF blockers)

archived sick care jobs saved or created!, commonly prescribed immune-suppressing mRNA medications not limited to ACE-inhibitors or ARBs

Mayo, common ACE inhibtors

Mayo, common Angiotnsin 2 receptor blockers (ABRs) a/k/a angiotensin II inhibitors

Age is not "the marker" of adverse outcome of COVID-19 disease.

ACE I and ACE2 represent elemental catalysts in every human cell regardless of age.

Comorbidity d/b/a degenerative diseases, or "pre-existing conditions", is the marker-concerning secondary conditions derived from a smorgasbord of mRNA drugs d/b/a "disease modifying" therapies, or "biologics," prescribed sales staff to disrupt immune system processes and hormonal regulation associated with this one enzyme modified by SARS RNA transcription within cells.

Academic controversy (notably unsupported by trial results involving human subjects captured by commonly prescribed ACE-modifying reactions) have acknowledged, pharmacology can neither control nor predict how those (ACE-receptor) drugs intercept, counter-indicate, or interdict dominant SARS-CoV-2 "vaccines" designed to bind this one, specific receptor region...

without regard to cascading adverse reactions (documented pathology) resulting in hospitalization, morbidity, and predictable death.

AFICT, the controversial T- and B-cell leucocyte "memory" power, arising from FAILED HIV/AID cocktail marketing confirms one fact: mRNA designers have no idea what they're dealing with. They can't even express  rational hypotheses pursuant to predictable viral "neutralization" by "cocktail" prescription.